Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 1165
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2019  |  Volume : 8  |  Issue : 3  |  Page : 114-118

Subcutaneous adipose tissue as a biomarker of pancreatic cancer: A pilot study in male patients


1 Unit of Diagnostic Imaging, Università Campus Bio-Medico di Roma, Rome; Unit of Diagnostic Imaging, Presidio Ospedaliero Orientale “M. Giannuzzi” Di Manduria Azienda Sanitaria Locale Di Taranto, Manduria, Italy
2 Unit of Diagnostic Imaging, Università Campus Bio-Medico di Roma, Rome, Italy

Date of Web Publication24-Jul-2019

Correspondence Address:
Federico Greco
Unit of Diagnostic Imaging, Università Campus Bio-medico di Roma, Via Alvaro Del Portillo, 21, 00128, Rome; Unit of Diagnostic Imaging, Presidio Ospedaliero Orientale “M. Giannuzzi” Di Manduria Azienda Sanitaria Locale Di Taranto, Via Mandonion, 1, 74024, Manduria
Italy
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ccij.ccij_36_19

Rights and Permissions
  Abstract 


Purpose: The purpose of this study was to evaluate the relationship between subcutaneous adipose tissue (SAT) and pancreatic cancer (PC) in male patients. Methods: In this retrospective study, two groups were included. Quantitative assessment of adipose tissue was performed by measuring total adipose tissue (TAT) area, visceral adipose tissue (VAT) area, and the SAT area in both the groups. Then, VAT/SAT ratio was calculated. Results: Statistically significant differences between the two groups were found in the SAT area (P < 0.05), TAT area was slightly above the threshold of significance, while no significant difference was found in the VAT area and VAT/SAT ratio. Conclusions: The results of this study suggest an association between SAT reduction and PC risk.

Keywords: Adrenomedullin, computed tomography, pancreatic cancer, subcutaneous adipose tissue


How to cite this article:
Greco F, Mallio CA, Cirimele V, Grasso RF, Zobel BB. Subcutaneous adipose tissue as a biomarker of pancreatic cancer: A pilot study in male patients. Clin Cancer Investig J 2019;8:114-8

How to cite this URL:
Greco F, Mallio CA, Cirimele V, Grasso RF, Zobel BB. Subcutaneous adipose tissue as a biomarker of pancreatic cancer: A pilot study in male patients. Clin Cancer Investig J [serial online] 2019 [cited 2019 Aug 17];8:114-8. Available from: http://www.ccij-online.org/text.asp?2019/8/3/114/263410




  Introduction Top


Pancreatic cancer (PC) is the fourth leading cause of cancer death worldwide.[1] Due to its aggressive nature, prognosis is poor and 5-year survival rates are as much as 9%.[1] Most PC patients die within 6 months after the diagnosis, usually showing locally advanced or metastatic disease.[2],[3] The large majority of pancreatic malignancies are pancreatic ductal adenocarcinoma (>90%).[4] Approximately 60%–70% of the lesions are located at the level of the head, neck, or uncinate process, 5%–10% at the body, and 10%–15% at the pancreatic tail.[5]

Jaundice commonly occurs in patients with a localized lesion in the head, neck, or uncinate process. Many patients have abdominal pain or back pain, followed by obstructive jaundice. Diabetes mellitus and pancreatitis may also be present. The most common manifestations of advanced disease are anorexia, weight loss, gastric outlet obstruction, and ascites.[6] PCs located in the left side of the gland may remain asymptomatic for a long time and be diagnosed when they reach a large size (4–5 cm), showing symptoms of advanced disease.[7] The incidence of thromboembolism in PC patients is 17%–57%.[8]

The severe and rapid loss of adipose tissue and skeletal muscle mass is an important contribution to early mortality in PC.[9] Many months before the onset of cachexia, weight loss occurs in PC patients.[10] The development of new-onset diabetes is paradoxically related to weight loss mostly related to a reduction of adipose tissue.[9],[10] It has been postulated that mediators secreted by PC are responsible for adipose tissue loss.[10] In particular, it has been shown that adrenomedullin (AM), contained in exosomes released by PC, determines lipolysis in the subcutaneous adipose tissue (SAT).[9] Computed tomography (CT) and magnetic resonance imaging are fundamental techniques for noninvasive tissue evaluation and characterization, including visceral adipose tissue (VAT) and SAT.[11],[12],[13],[14],[15],[16],[17]

We hypothesized that SAT reduction, as measured with a quantitative CT imaging-based approach, is associated with the occurrence of PC in male patients.


  Methods Top


Patients

In this retrospective study, two groups of patients were included: the PC group and the control group. All of the recruited participants underwent a CT examination in our institution between December 2012 and May 2016.

In the PC group, a total of 20 male patients with PC at the first diagnosis were enrolled (mean age: 73.4 years, range: 44–83).

All CT images were acquired for disease staging. The disease staging was 4 T1N0M0, 1 T1N1M0, 2 T2N0M0, 1 T2N1M0, 3 T3N0M0, and 9 T3N1M0.

None of the patients enrolled in the PC group had a past medical history of malignancies before the diagnosis of PC.

We included 20 male patients who have undergone a chest–abdomen CT for preoperative cardiovascular surgery as a control group (mean age: 69.4 years, range: 57–82) because of the fact that abdominal CT is not usually performed in healthy patients.

Patients included in the control group underwent the following cardiac surgery: mitral valve replacement (6), aortic valve replacement (6), mitral and tricuspid valve replacement (1), left atrial myxoma resection (1), combined coronary artery bypass and mitral valve replacement (3), combined coronary artery bypass and aortic valve replacement (1), combined coronary artery bypass with mitral and tricuspid valve replacement (1), and aortic valve and ascending aorta replacement (1). None of the patients of the control group had a history of malignancies.

Computed tomography analysis

CT scans were performed with SOMATOM Sensation 64, Siemens, Forchheim, Germany. OsiriX MD version 2.6 was used to analyze cross-sectional CT images to calculate total adipose tissue (TAT) area, VAT area, and SAT area. All measurements were obtained as areas (cm2), on the axial plane 3 cm above the lower margin of L3 [Figure 1].[12],[18]
Figure 1: Axial computed tomography images showing the regions of interest of the total adipose tissue area (a), visceral adipose tissue area (b), and subcutaneous adipose tissue area (c)

Click here to view


Statistical analysis

The TAT, VAT, and SAT areas and the VAT/SAT ratio were compared using the Student's t-test between the two groups. The level of statistical significance was considered to be P < 0.05.


  Results Top


Statistically significant differences between the two groups were found in the SAT area (P < 0.05), TAT area was slightly above the threshold of significance, while no significant difference was found in the VAT area and VAT/SAT ratio [Figure 2]. The results are summarized in [Table 1].
Figure 2: Mean value of total adipose tissue, visceral adipose tissue, and subcutaneous adipose tissue areas and visceral adipose tissue/subcutaneous adipose tissue ratio in control and pancreatic cancer groups

Click here to view
Table 1: Mean of the two groups and Student's t-test results

Click here to view



  Discussion Top


We have evaluated the SAT area in PC male patients.

The results show a significant difference of SAT between the control group and the PC group, suggesting an association between the reduction of SAT and PC.

In PC-induced diabetes, as well as in type 2 diabetes, there is evidence of beta-cell dysfunction and peripheral insulin resistance. However, the control of glucose level is challenging in PC-induced diabetes, leading to continuous and severe weight loss. Indeed, diabetes and cachexia can be paraneoplastic phenomena induced by PC.[10]

Cancerous cachexia is a multifactorial metabolic syndrome that leads to gradual functional deterioration. The loss of adipose tissue and skeletal muscles of cancer cachexia cannot be completely resolved by conventional nutritional support.[19] The depletion of adipose tissue as well as muscle is associated with a poor outcome.[20] Cachexia affects 80% of all cancer patients and is the direct cause of 22%–40% of cancer deaths.[21],[22],[23]

The reduction of adipose tissue in cachexia is determined by several factors: the increased lipolysis of the triglycerides, the reduction of fatty acid synthase and lipoprotein lipase activity that determine a reduction of lipogenesis and fatty acid esterification, and the interruption of organization and development of adipose tissue due to impaired turnover of adipocytes.[20],[24],[25],[26]

Weight loss precedes the appearance of PC symptoms several months before. This weight loss is not due to cachexia.[10] Moreover, weight loss occurs months before the onset of diabetes. This phenomenon could be an important predictor of the development of PC-induced diabetes.[27]

Studies show that fat loss occurs more quickly and earlier than muscle mass loss.[28],[29] It has been shown that, during the development of the disease, the adipose tissue, in particular the subcutaneous, is a possible relative systemic reservoir of inflammatory molecules.[30]

Adipose tissue atrophy is characterized by the reduction in size of the adipocytes, associated with a significant increase in fibrosis of tissue matrix.[31]

Fibrosis and inflammatory cell infiltration induced by cachexia have been shown in SAT of gastrointestinal cancer patients; macrophages and lymphocytes were present in the fibrotic areas of SAT.[32]

Surgical removal of subcutaneous fat by liposuction did not affect insulin resistance, whereas surgical removal of visceral fat led to improvements or to equivocal result.[33],[34],[35]

In our study, we did not find a significant difference of mean VAT values between the PC group and the control group.

The progressive worsening of glycemia and insulin resistance is probably controlled by the VAT which remains substantially conserved, while the reduction of SAT could explain weight loss.[10]

It has been shown that the exosomes released by PC induce lipolysis at the SAT level, determining the paraneoplastic effect. The lipolytic effect is induced by AM, contained in exosomes secreted by the PC. The plasma levels of PC exosomes containing AM were higher than those of the non-PC controls, even though a certain degree of variability was found between the participants. In addition, PC patients had a total number of exosomes much higher than non-PC controls. Furthermore, the lipolytic effect promoted by the exosomal AM was interrupted with AM inhibitor treatment.[9]

The results of our study show significant differences in the mean SAT area between PC patients and controls. SAT area could be considered a promising quantitative imaging biomarker of PC occurrence [Figure 3].
Figure 3: Axial computed tomography images show the regions of interest of the subcutaneous adipose tissue area in control (a) and pancreatic cancer (b) groups

Click here to view


The limitations of our study are as follows: retrospective analysis, lack of clinical information such as body mass index and hormonal status, the low number of patients, and different cancer staging.

Future studies should be performed in female patients to see if similar changes in adipose tissue can be found.

In addition, further studies with a greater number of patients should be performed to see the modifications of SAT area in the different PC stages.


  Conclusions Top


The results of this study suggest an association between SAT reduction and PC risk.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol 2015;42:8-18.  Back to cited text no. 1
    
2.
Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013;62:317-26.  Back to cited text no. 2
    
3.
Stathis A, Moore MJ. Advanced pancreatic carcinoma: Current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72.  Back to cited text no. 3
    
4.
Haugen F, Labori KJ, Noreng HJ, Buanes T, Iversen PO, Drevon CA. Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer. Arch Physiol Biochem 2011;117:78-87.  Back to cited text no. 4
    
5.
Solcia E, Capella C, Kloppel G. Tumors of the Exocrine Pancreas. Tumors of the Pancreas. Washington: Armed Forces Institute of Pathology; 1997.  Back to cited text no. 5
    
6.
Royal RE, Wolff RA, Crane CH. Cancer principles and practice of oncology. 8th ed. Vol. 1. Philadelphia, USA: Lippincott Williams and Wilkins; 2008.  Back to cited text no. 6
    
7.
Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.  Back to cited text no. 7
    
8.
Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5:655-63.  Back to cited text no. 8
    
9.
Sagar G, Sah RP, Javeed N, Dutta SK, Smyrk TC, Lau JS, et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut 2016;65:1165-74.  Back to cited text no. 9
    
10.
Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013;10:423-33.  Back to cited text no. 10
    
11.
Prado CM, Heymsfield SB. Lean tissue imaging: A new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr 2014;38:940-53.  Back to cited text no. 11
    
12.
Greco F, Cirimele V, Mallio CA, Beomonte Zobel B, Grasso RF. Increased visceral adipose tissue in male patients with clear cell renal cell carcinoma. Clin Cancer Investig J 2018;7:132-6.  Back to cited text no. 12
  [Full text]  
13.
Mallio CA, Greco F, Pacella G, Schena E, Beomonte Zobel B. Gender-based differences of abdominal adipose tissue distribution in non-small cell lung cancer patients. Shanghai Chest 2018;2. [doi: 10.21037/shc. 2018.03.03].  Back to cited text no. 13
    
14.
Del Buono R, Sabatino L, Greco F. Neck fat volume as a potential indicator of difficult intubation: A pilot study. Saudi J Anaesth 2018;12:67-71.  Back to cited text no. 14
    
15.
Greco F, Faiella E, Santucci D, Mallio CA, Nezzo M, Quattrocchi CC, et al. Imaging of renal medullary carcinoma. J Kidney Cancer VHL 2017;4:1-7.  Back to cited text no. 15
    
16.
Greco F, Mallio CA, Cirimele V, D'Alessio P, Beomonte Zobel B, Grasso RF. Imaging of renal angiomyolipomatosis. J Ren Hepat Disord 2018;2:10-9.  Back to cited text no. 16
    
17.
Greco F, Faiella E, Santucci D, Cirimele V, Nezzo M, Beomonte Zobel B, Grasso RF. Modelli di linfoma renale e diagnosi differenziale. G Ital Radiol Med 2018;2:240-4.  Back to cited text no. 17
    
18.
Noumura Y, Kamishima T, Sutherland K, Nishimura H. Visceral adipose tissue area measurement at a single level: Can it represent visceral adipose tissue volume? Br J Radiol 2017;90:20170253.  Back to cited text no. 18
    
19.
Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381-410.  Back to cited text no. 19
    
20.
Murphy RA, Wilke MS, Perrine M, Pawlowicz M, Mourtzakis M, Lieffers JR, et al. Loss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients. Clin Nutr 2010;29:482-7.  Back to cited text no. 20
    
21.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-95.  Back to cited text no. 21
    
22.
Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol 2010;26:146-51.  Back to cited text no. 22
    
23.
Argilés JM, Stemmler B, López-Soriano FJ, Busquets S. Nonmuscle tissues contribution to cancer cachexia. Mediators Inflamm 2015;2015:182872.  Back to cited text no. 23
    
24.
Das SK, Hoefler G. The role of triglyceride lipases in cancer associated cachexia. Trends Mol Med 2013;19:292-301.  Back to cited text no. 24
    
25.
Agustsson T, Rydén M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007;67:5531-7.  Back to cited text no. 25
    
26.
Rydén M, Andersson DP, Bernard S, Spalding K, Arner P. Adipocyte triglyceride turnover and lipolysis in lean and overweight subjects. J Lipid Res 2013;54:2909-13.  Back to cited text no. 26
    
27.
Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 2011;40:768-72.  Back to cited text no. 27
    
28.
Arner P. Medicine. Lipases in cachexia. Science 2011;333:163-4.  Back to cited text no. 28
    
29.
Batista ML Jr., Neves RX, Peres SB, Yamashita AS, Shida CS, Farmer SR, et al. Heterogeneous time-dependent response of adipose tissue during the development of cancer cachexia. J Endocrinol 2012;215:363-73.  Back to cited text no. 29
    
30.
Batista ML Jr. Olivan M, Alcantara PS, Sandoval R, Peres SB, Neves RX, et al. Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine 2013;61:532-9.  Back to cited text no. 30
    
31.
Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, Rydén M, et al. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer 2011;104:441-7.  Back to cited text no. 31
    
32.
Batista ML Jr., Henriques FS, Neves RX, Olivan MR, Matos-Neto EM, Alcântara PS, et al. Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 2016;7:37-47.  Back to cited text no. 32
    
33.
Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004;350:2549-57.  Back to cited text no. 33
    
34.
Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: An adipokine-mediated process? Diabetes 2002;51:2951-8.  Back to cited text no. 34
    
35.
Thörne A, Lönnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: Omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002;26:193-9.  Back to cited text no. 35
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Methods
Results
Discussion
Conclusions
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed78    
    Printed1    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal